Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic ... Read More
GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis' 36.5% stake in their consumer healthcare joint venture for $13 billion. ... Read More
Novartis to acquire Advanced Accelerator Applications for $3.9bn to enhance oncology portfolio
Novartis, the Switzerland-based global healthcare giant, has announced its decision to acquire Advanced Accelerator Applications (AAA), a French radiopharmaceutical company, for $3.9 billion. This acquisition ... Read More
FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority ... Read More